Issue: November/December 2016, Posted Date: 12/20/2016
Leading Developer of Multi-Layer Oral Thin Film Completes Going Public Transaction
Pharmaceutical, a pre-eminent developer and manufacturer of advanced oral thin
film for use in pharmaceutical, veterinary, and buccal and dermal
over-the-counter applications, recently announced the completion of a going
public transaction and the issuance of its new stock symbol - CURR.
“After nearly 6 years of intense R&D activities, CURE Pharmaceutical is
pleased to finally become a publicly traded entity, and anticipates a series of
exciting business development announcements in the months to come,” said Rob
Davidson, CEO of CURE Pharmaceutical.
in Oxnard, CA, CURE Pharmaceutical has developed and manufactures the most
advanced oral thin film (CureFilm™) on the market today supported by its in-house,
industry-leading full-service cGMP manufacturing facility. CureFilm is more
stable and durable than other oral thin films, with the ability to augment the
dissolution for the intended rate of release through the buccal or
gastrointestinal system. The technology enables differentiation within large
therapeutic categories and potentially improves patient compliance, through its
patented application of creating multiple layers, and sub-encapsulation of the
delivered compound, potentially improving onset of action, lowering dosing, and
enhancing, efficacy, thereby widening the therapeutic index.
CURE Pharmaceutical is now traded under the symbol CURR. For more
information about CURE Pharmaceutical, visit www.curepharmaceutical.com.
This record has been viewed 368 times.